Evaluating the Efficacy of Vitamin D Add-on Therapy on Treatment of Positive, Negative and Cognitive Symptoms in Patients with Chronic Schizophrenia; A Double Blind Clinical Trial

author

  • ,
Abstract:

Background: Vitamin D can be effective in treating some symptoms of schizophrenia, and with better control of vitamin D levels and supplementation, there is a potential for reducing this disease. But due to small number of studies, more studies are needed in this area. The aim of this study was to determine the efficacy of vitamin D as an adjunct to the positive, negative, and cognitive symptoms of people with chronic schizophrenia. Methods: The present study is a double-blind clinical trial. A total of 30 patients who were eligible for inclusion criteria were selected randomly. The Positive and Negative Syndrome Scale (PANSS) scale was used to determine the status of positive symptoms, negative symptoms and general psychopathology, and The Mini-Mental State Examination (MMSE) to determine cognitive status when entering the study and at the end of the eighth week. Results: There was no significant difference between the two groups in terms of mean negative symptoms before and after the study. The overall symptoms score based on PANSS did not show a significant difference before and after treatment with vitamin D (P=0.8). There was no significant difference between the two intervention and control groups regarding the mean of general symptoms before and after the study. Also, there was no significant difference between the two intervention and control groups before and after the study in terms of mean total score based on PANSS. Conclusion: Adding vitamin D to the standard treatment of schizophrenia did not have a significant effect on the improvement of positive, negative and invasive symptoms and general symptoms.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Treatment-Responsiveness of Negative Symptoms in Schizophrenia: A double-blind placebo-control clinical trial

Background: The negative symptoms of schizophrenia remain a major clinical challenge. Nortriptyline is a serotonin and noradrenalin reuptake inhibitor and belongs to secondary amine tricycles. The aim of this study is to evaluate the effect of nortriptyline on the negative symptoms of schizophrenia. Methods: This study is a six-week randomized placebo-control trial of nortriptyline or placebo a...

full text

Effects of Atorvastatin on negative sign in chronic schizophrenia: A double blind clinical trial

The aim of this study was to evaluate the effects of Atorvastatin on negative symptoms in patients with chronic schizophrenia. The study was a prospective, double-blind, 6-week trial. Forty patients participated in the study; 19 patients were assigned to the Atorvastatin group as well as 21 patients to the placebo group. For assessing negative signs, we used Scale for the Assessment of Negative...

full text

Effects of Bromocriptine on Negative Symptoms of Schizophrenia: A Double Blind Clinical Trial

Negative symptoms are still a major obstacle in the recovery of schizophrenic patients. Many attempts to develop novel drugs affecting negative symptoms of schizophrenia have yielded insignificant results. This study evaluates the effects of bromocriptine, a dopamine agonist, on negative symptoms of schizophrenia utilizing a placebo-controlled crossover double-blind clinical trial. Methodology:...

full text

Effects of Atorvastatin on negative sign in chronic schizophrenia: A double blind clinical trial

The aim of this study was to evaluate the effects of Atorvastatin on negative symptoms in patients with chronic schizophrenia. The study was a prospective, double-blind, 6-week trial. Forty patients participated in the study; 19 patients were assigned to the Atorvastatin group as well as 21 patients to the placebo group. For assessing negative signs, we used Scale for the Assessment of Negative...

full text

Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...

full text

Effect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial

Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 37  issue 3

pages  171- 177

publication date 2020-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023